health
BMJ editorial calls for clearer records of dissent in drug approvals
A BMJ editorial argues that drug regulatory decisions should show more clearly when licensing committees disagree about benefits, risks and evidentiary uncertainty. It highlights the European Medicines Agency’s formal process for recording dissent.